Aug 3, 2026
Supernus Pharmaceuticals and Indivior Pharmaceuticals Agree to All-Stock Merger Creating $2.2 Billion CNS Drug Company
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced an all-stock merger to create a combined company with approximately $2.2 billion in annual revenue and a portfolio of 11 commercialized medicines focused on neurological, psychiatric, and addiction-related conditions. The deal, described as a merger of equals, is expected to generate $125 million in cost savings.
9 sources
00